Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Therapeutic Pearls for Managing GPP and Palmoplantar Pustulosis
Description
The presentation discusses generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP), analyzing their classification, prevalence, and treatment strategies. GPP is described as a rare yet potentially life-threatening condition, often triggered by infections, pregnancy, and certain medications, with significant advances in understanding its genetic basis, particularly the role of interleukin 36. The discussion highlights the effectiveness of spasolamab, a biologic targeting interleukin 36, showing promising results in reducing pustules during flare-ups and offering preventive treatment options. Conversely, PPP, which affects a larger population but is less severe, presents diagnostic challenges due to its similarity to other skin conditions. Treatment options include various traditional and experimental therapies, yet none have shown significant superiority over placebo. The conversation also considers the possibility of reclassifying drug-induced GPP and emphasizes the importance of considering the underlying causes of pustular eruptions. Overall, the therapeutic pearls provided underscore the potential of both traditional psoriasis medications and emerging therapies, while recognizing the complexities of effectively managing these conditions.
View moreConclusions
- Generalized Pustular Psoriasis (GPP) is a rare but potentially life-threatening condition with varying genetic factors and triggers.
- The discovery of the IL36RN mutation has advanced our understanding of GPP and its treatment options.
- Spesolimab, a biologic targeting the IL-36 receptor, has shown significant efficacy in treating GPP flares.
- In a clinical trial, 54% of patients on spesolimab showed complete resolution of pustules within one week.
- Maintenance treatment with spesolimab leads to a significant reduction in the frequency of GPP flares over time.
- Quality of life for GPP patients remains severely impacted even during periods of remission, necessitating proactive treatment strategies.
- Recent studies suggest that traditional psoriasis biologics may also be effective in treating GPP.
- Drug-induced GPP presents similarly to classic GPP, leading to recommendations for reconsidering disease classification.
- Palmoplantar Pustulosis (PPP) affects a greater number of individuals and significantly impacts quality of life but is less life-threatening than GPP.
- Pharmacologic treatments for PPP include traditional psoriasis medications, with varying levels of effectiveness reported.
- Evidence for the efficacy of newer treatments for PPP is still emerging, and many treatments lack robust clinical data.
- Smoking cessation appears to have a positive effect on the severity of PPP, suggesting lifestyle changes may be beneficial.
- Recent studies show that while there are promising data for new therapies, challenges remain with high placebo rates in trials for PPP.
- Lo"fvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of generalised pustular psoriasis in Sweden - a population-based register.
- Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 Oct 28;402(10412):1541-1551. doi: 10.1016/S0140-6736(23)01378-8. Epub 2023 Sep 19. PMID: 37738999.
- Kharawala S, et al. The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review. Expert Rev Clin Immunol. 2020 Mar;16(3):253-266. PMID: 32073337.
- Kim SR, Choi YG, Jo SJ. Effect of smoking cessation on psoriasis vulgaris, palmoplantar pustulosis and generalized pustular psoriasis. Br J Dermatol. 2024 Jul 16;191(2):225-232. doi: 10.1093/bjd/ljae130. PMID: 38534203.
- Spencer RK, Jin JQ, Elhage KG, Davis MS, Hakimi M, Bhutani T, Liao W. Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network clinical trials. J Am Acad Dermatol. 2023 Aug;89(2):423-425. doi: 10.1016/j.jaad.2023.04.043. Epub 2023 Apr 29. PMID: 37121476.
- Huang IH, Wu PC, Chiu HY, Huang YH. Small-Molecule Inhibitors and Biologics for Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis. Am J Clin Dermatol. 2024 May;25(3):347-358. doi: 10.1007/s40257-024-00849-0. Epub 2024 Mar 4. PMID: 38438782.